Skip to main content
OpenTrials
Completed

NCT Number: NCT04081870

IS Three d Power Doppler of the Endometrial and Subendometrial Regions Effective in Predicting Endometrial Implantation?

Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day (progest, micronized progesterone 100mg, Technopharma, Egypt, for pharco pharmaceuticals, Amriya- Alexandria). Five days following ovum pick up, the embryos were transferred at the blastocyst stage.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Observational

About this study

All women underwent long agonist protocol for controlled ovarian hyperstimulation described by Chang et al. (14) The GnRH agonist was started in the previous mid-luteal phase (decapeptylR R 0.1mg, Triptorelin-Acetate, Ferring GmbH, Wittland 11, D-24109, and Kiel, Germany). After the confirmation of pituitary down regulation (serum LH less than 5 m IU/ml and serum E2 less than 50 pg /ml), the HMG ampoules were started by 225 IU/day (Gonapure 75 IU, IBSA Institute Biochimique SA, Switzerland). During the follow up of overstimulation, the doses were adjusted according to the response of patient. All women underwent serial TVS until at least three dominant follicles were reached in every woman. When the dominant follicles reached 18-20 mm, HCG 10000 (Choriomon 5000 IU, IBSA Institute Biochimique SA, Switzerland) was administered. Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration. The luteal phase was supported by progesterone 300 mg per day (progest, micronized progesterone 100mg, Technopharma, Egypt, for pharco pharmaceuticals, Amriya- Alexandria). Five days following ovum pick up, the embryos were transferred at the blastocyst stage. Twelve days later to embryo transfer, serum pregnancy test was done and if positive (chemical pregnancy), the clinical pregnancy was confirmed by TVS for detection of gestational sacs and embryo cardiac activity. The ongoing pregnancy was detected by abdominal ultrasound at 12 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

a

  • age; 22-35 years,
  • BMI; less than 35 kg/m2,
  • Husband with oligo- or oligoasthenospermia.

Exclusion criteria

  • \\1-gross uterine and tubal pathology,
  • 2-Development of OHSS,
  • 3-poor responders,
  • 4-failure of oocyte fertilization or failure of the embryos to reach the blastocyst stage and
  • 5-Refusal to participate in the study at any step of the ICSI cycle.

Treatment and study plan

3D power doppler US

Diagnostic Test

Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.

Primary outcomes

  1. chemical pregnancy

    Time frame: 14 day

    positive pregnancy test

  2. the clinical pregnancy

    Time frame: 28 day

    was confirmed by TVS for detection of gestational sacs and embryo cardiac activity.

  3. The ongoing pregnancy

    Time frame: 3 months

    was detected by abdominal ultrasound at 12 weeks.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

IS Three d Power Doppler of the Endometrial and Subendometrial Regions Effective?

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Sep 9, 2019
Registry last updated
Sep 11, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.